Edition:
United States

People: Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

3.50USD
18 Apr 2019
Change (% chg)

$-0.03 (-0.85%)
Prev Close
$3.53
Open
$3.52
Day's High
$3.57
Day's Low
$3.43
Volume
56,598
Avg. Vol
106,593
52-wk High
$7.16
52-wk Low
$3.31

Hellums, Rhonda 

Ms. Rhonda Hellums is Chief Financial Officer, Treasurer of the company. Rhonda Hellumshas more than 20 years of experience in finance and operations, specifically bringing a deep skillset in strategic planning, systems implementation, business development and investor relations. Prior to her role at Aratana, Hellums served as Director of Global Finance at Kinetic Concepts, Inc. (KCI), a global medical device company with more than$1 billionin revenues and 5,000 employees, where she was responsible for global finance functions, portfolio valuation and planning. Hellums served as Vice President of Finance for Enzon Pharmaceuticals where she oversaw$180 millionin investments, investor relations, as well as coordinated key components of the$300 millionsale of Enzon's specialty pharmaceutical business. She worked at ILEX Oncology, Inc. as the Director of Finance and Strategic Planning when it was acquired by Genzyme Corporation. Subsequently, Genzyme named her Director of Finance, Alliance and Strategic Planning. Early in her career, Hellums was a management consultant for KPMG, LLC. and client EG&G, Inc., a division of URS Corporation, hired her to serve as their Division Controller. Hellums earned her M.B.A. from the University of Texas at San Antonio and a B.A. in Accounting and Information Systems from the University of Texas at San Antonio.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --